LPPEPTIDE | AOD 9604 10mg | 10mg x 10 vials | 10 vials / box

What is AOD 9604?

AOD 9604 is a synthetic peptide fragment originally derived from growth hormone research. It was designed as a modified version of the C-terminal portion of human growth hormone (hGH). Researchers have explored its potential relationship to lipid metabolism and adipose tissue breakdown.

Research context

Research on AOD 9604 has focused on its relationship to lipid metabolism, obesity models, and metabolic pathways. Findings suggest it may operate differently than growth hormone, particularly in relation to receptor interaction and lean body mass. While animal and early human studies indicate possible roles in adipose regulation, the compound remains under investigation across several scientific fields.

Compliance notice

AOD 9604 is supplied for research use only. It is not for human or veterinary use, not for consumption, and statements on this page are reference context rather than medical claims.

Reference literature focus

AOD-9604 is a synthetic analog of the C-terminal fragment (177–191) AOD-9604 stimulates lipolysis (fat breakdown) without the unwanted growth-promoting or insulin-antagonizing effects of full-length hGH. AOD-9604 is a potent lipolytic tool in animal models and researchers focus on its regenerative properties in joint health and its ability to modulate beta3 adrenergic receptors without the systemic risks of growth hormone.

Study design notes

Use the LPPeptide product knowledge record, current LPPeptide COA, and internal lab SOP to confirm identity, concentration, and endpoints before this material enters a study. The matched LPPeptide reference specification is 5mg x 10 vials / 10mg x 10 vials.

LPPeptide handling reference

Reconstitution Add 3.0 mL of sterile water for injection (WFI) to the lyophilized powder. The resulting concentration is approximately 0.333 mg/mL (333 μg/mL). Storage Conditions for Lyophilized Product The lyophilized powder should be stored at -20°C, protected from light and moisture. Under these recommended storage conditions, the product remains stable for more than one year. Dosage and Administration Typical daily dosage range: 300–500 μg once daily.

Preparation

AOD 9604 10mg ships as Lyophilized powder. Reconstitution note: LPPEPTIDE knowledge source: add 3.0 mL sterile water for about 0.333 mg/mL. Reference range is once daily 300-500 mcg. At this concentration, 1 U is about 3.33 mcg.. Record the final concentration and preparation date in the study log.

Storage

Lyophilized: -20 deg C, dry and dark, with year-plus stability when protected. Reconstituted: 2-8 deg C, use within about 3-4 weeks, and avoid freezing.. Follow the most current lot-specific handling record whenever it is available.

Safety observations

Published human outcome data is limited. Track metabolic markers and study tolerance signals under controlled research conditions.

Contraindications

Do not use AOD 9604 outside qualified research workflows. Review the current SDS, COA, and protocol exclusions before handling.

Interaction review

Use caution with other growth hormone axis, metabolic, or glucose-handling research materials.

Certificate of Analysis

Each LPPeptide lot should be confirmed against current batch documentation before shipment or study use. This product page keeps 10AD visible so the SKU can be matched to the active COA.

Current catalog summary

• SKU: 10AD
• Product: AOD 9604 10mg
• Storefront specification: 10mg x 10 vials /box
• LPPeptide reference specs: 5mg x 10 vials / 10mg x 10 vials
• Listed box price: $174.00 USD
• Reference: LPPeptide product knowledge record

Testing checklist

• Peptide identity or material identity
• HPLC purity or assay result where applicable
• Batch ID and test date
• Sterility/endotoxin or accessory checks when applicable
• Residual solvent and handling notes where applicable

Direct catalog supply

LPPeptide product pages use our own SKU, package, price, and stock data first. LPPeptide knowledge mapping adds compound education, handling notes, and specification checks while lot-specific editorial content is being prepared.

Lot-specific content

For final release decisions, use the current product record, COA, handling sheet, and research SOP as the highest-priority source for this page.